BR0010985A - Antagonistas de receptor de il-8 - Google Patents

Antagonistas de receptor de il-8

Info

Publication number
BR0010985A
BR0010985A BR0010985-1A BR0010985A BR0010985A BR 0010985 A BR0010985 A BR 0010985A BR 0010985 A BR0010985 A BR 0010985A BR 0010985 A BR0010985 A BR 0010985A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
chemokine
interleukin
formula
treatment
Prior art date
Application number
BR0010985-1A
Other languages
English (en)
Inventor
Deborah L Bryan
John G Gleason
Katherine L Widdowson
Gregory M Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0010985A publication Critical patent/BR0010985A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR DE IL-8". Esta invenção refere-se a novos compostos de Fórmula (I), composições farmacêuticas e seu uso no tratamento de estados de doença mediados pela quimiocina, interleucina-8 (IL-8).
BR0010985-1A 1999-06-16 2000-06-16 Antagonistas de receptor de il-8 BR0010985A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16
PCT/US2000/016813 WO2000076516A1 (en) 1999-06-16 2000-06-16 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0010985A true BR0010985A (pt) 2002-03-26

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010985-1A BR0010985A (pt) 1999-06-16 2000-06-16 Antagonistas de receptor de il-8

Country Status (22)

Country Link
EP (1) EP1191934A4 (pt)
JP (1) JP2003501471A (pt)
KR (1) KR20020009635A (pt)
CN (1) CN1494424A (pt)
AR (1) AR029368A1 (pt)
AU (1) AU766086B2 (pt)
BR (1) BR0010985A (pt)
CA (1) CA2377397A1 (pt)
CZ (1) CZ20014490A3 (pt)
EC (2) ECSP003525A (pt)
HK (1) HK1044716A1 (pt)
HU (1) HUP0202019A3 (pt)
IL (1) IL146214A0 (pt)
MX (1) MXPA01013287A (pt)
NO (1) NO20016065D0 (pt)
NZ (1) NZ515232A (pt)
PE (1) PE20010319A1 (pt)
PL (1) PL352218A1 (pt)
TR (1) TR200103690T2 (pt)
UY (1) UY26209A1 (pt)
WO (1) WO2000076516A1 (pt)
ZA (1) ZA200110203B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0344425B1 (en) * 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.

Also Published As

Publication number Publication date
WO2000076516A1 (en) 2000-12-21
PL352218A1 (en) 2003-08-11
AU766086B2 (en) 2003-10-09
HUP0202019A2 (en) 2002-10-28
TR200103690T2 (tr) 2002-05-21
AR029368A1 (es) 2003-06-25
AU5748200A (en) 2001-01-02
PE20010319A1 (es) 2001-05-24
HK1044716A1 (zh) 2002-11-01
UY26209A1 (es) 2000-12-29
NZ515232A (en) 2004-02-27
CN1494424A (zh) 2004-05-05
EP1191934A1 (en) 2002-04-03
HUP0202019A3 (en) 2003-03-28
ZA200110203B (en) 2002-09-11
NO20016065L (no) 2001-12-12
EP1191934A4 (en) 2004-02-04
ECSP003525A (es) 2002-01-25
CA2377397A1 (en) 2000-12-21
IL146214A0 (en) 2002-07-25
NO20016065D0 (no) 2001-12-12
CZ20014490A3 (cs) 2002-07-17
MXPA01013287A (es) 2002-06-04
ECSP003528A (es) 2002-01-25
JP2003501471A (ja) 2003-01-14
KR20020009635A (ko) 2002-02-01

Similar Documents

Publication Publication Date Title
BR0110968A (pt) Antagonistas dos receptores de il-8
BR9916159A (pt) Sulfonamidas de hidróxi-difenil-uréia comoantagonistas dos receptores de il-8
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
BR9612779A (pt) Antagonistas ao receptor de il-8
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CY1106514T1 (el) Ανταγωνιστες υποδοχεων il-8
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
ATE419845T1 (de) Il-8-rezeptor-antagonisten
BR9909486A (pt) Compostos calcilìticos
BR0108866A (pt) Antagonistas de receptor de il-8
PT1129096E (pt) Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
BR9807085A (pt) Antagonistas de receptor de il-8
NZ514696A (en) IL-8 receptor antagonists
BR0108867A (pt) Antagonistas de receptor il-8
WO2001068569A3 (en) Il-8 receptor antagonists
BR0010843A (pt) Antagonistas de receptores de il-8
BR0108749A (pt) Antagonistas de receptor il-8
BR0010863A (pt) Antagonistas de receptores de il-8
BR0010985A (pt) Antagonistas de receptor de il-8
MY143477A (en) Il-8 receptor antagonists
WO2000072800A3 (en) Il-8 receptor antagonists
UY26207A1 (es) Antagonistas de los receptores de la il-8.
BR9815951A (pt) Antagonistas do receptor de il-8
BR0109196A (pt) Antagonistas dos receptores da il-18

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.